Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 4
Describing the Value of ctDNA in Clinical Practice
The key opinion leaders share their approaches for communicating about circulating tumor DNA and minimal residual disease to patients, emphasizing the significance of ctDNA testing in detecting MRD.
EP: 1.Overview of colorectal cancer and its management
EP: 2.Background on Colorectal Cancer Screening and its Role in Patient Care
EP: 3.Circulating Tumor DNA Detection Techniques
Now Viewing
EP: 4.Describing the Value of ctDNA in Clinical Practice
EP: 5.Clinical study of ctDNA-based MRD detection and INTERCEPT program update
EP: 6.Recent findings from BESPOKE
EP: 7.Incorporating ctDNA-Based MRD Testing and Study Findings Into Clinical Practice
EP: 8.Key Considerations for Selection of ctDNA Detection Methods
EP: 9.Clinical Utility of ctDNA Testing
EP: 10.Barriers to Implementing ctDNA Testing
EP: 11.ctDNA Testing in a CRC Clinical Scenario
EP: 12.ctDNA to Inform Adjuvant Therapy and the CIRCULATE Trial
EP: 13.Interpreting and Communicating ctDNA Results
EP: 14.Addressing Gaps in ctDNA Testing
EP: 15.Exploring the Future of ctDNA and Novel Treatment Strategies
- Mackenzie Phillips: How do you describe ctDNA and MRD to patients?
- Jing Yi: Why do you think it’s important to do ctDNA testing for MRD?
Recent Videos
Related Content
